
Ugur Sahin
Vermogen: 3 845 M $ op 31-05-2026

Vermogen: 3 845 M $ op 31-05-2026
Ugur Sahin, oprichter van BioNTech SE, Ganymed Pharmaceuticals AG, Ci3 Management UG en TRON - Translationale Onkologie an der Universittsmedizin der, is momenteel Chief Executive Officer voor BioNTech SE en Managing Director bij reBOOST Management GmbH (een dochteronderneming van BioNTech SE) en Managing Director bij Medine GmbH. Dr. Sahin is ook professor aan de Universittsmedizin der Johannes Gutenberg-Universitt Mainz. Daarvoor was hij Chief Medical Officer bij Ganymed Pharmaceuticals AG en Co-Managing Director bij TRON - Translationale Onkologie an der Universittsmedizin der. Dr. Sahin promoveerde aan de Universitt zu Kln.
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
BIONTECH SE 16,59% | 31-03-2026 | 40.076.320 ( 16,59% ) | 3 845 M $ | 31-05-2026 |
| Bedrijven | Functie | Begin |
|---|---|---|
| BIONTECH SE | Algemeen Directeur | 02-06-2008 |
reBOOST Management GmbH
reBOOST Management GmbH Miscellaneous Commercial ServicesCommercial Services Provides management consultancy services | Algemeen Directeur | 23-10-2018 |
Medine GmbH
Medine GmbH Miscellaneous Commercial ServicesCommercial Services Provides management consultancy services | Algemeen Directeur | 14-03-2011 |
Universitätsmedizin der Johannes Gutenberg-Universität Mainz
Universitätsmedizin der Johannes Gutenberg-Universität Mainz Medical/Nursing ServicesHealth Services Provides health care facilities and services | Corporate Officer/Principal | 01-01-2014 |
Helmholtz Institute For Translational Oncology | Corporate Officer/Principal | - |
BioNTech Delivery Technologies GmbH
BioNTech Delivery Technologies GmbH Miscellaneous Commercial ServicesCommercial Services Engages in research and development of immunotherapies | Algemeen Directeur | - |
| Bedrijven | Functie | Einde |
|---|---|---|
TRON - Translationale Onkologie an der Universitätsmedizin der
TRON - Translationale Onkologie an der Universitätsmedizin der Miscellaneous Commercial ServicesCommercial Services Operates as biopharmaceutical research organization | Algemeen Directeur | 01-01-2019 |
Ganymed Pharmaceuticals AG
Ganymed Pharmaceuticals AG BiotechnologyHealth Technology Develops antibodies for the treatment of solid cancers | Oprichter | 30-07-2010 |
Ci3 Management UG | Oprichter | - |
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
| Bedrijven in privébezit | 10 |
|---|---|
Ganymed Pharmaceuticals AG
Ganymed Pharmaceuticals AG BiotechnologyHealth Technology Develops antibodies for the treatment of solid cancers | Health Technology |
Universität zu Köln
Universität zu Köln Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
BioNTech SE
BioNTech SE BiotechnologyHealth Technology Develops immunotherapies and mRNA-based vaccines to treat cancer & infectious diseases | Health Technology |
Universitätsmedizin der Johannes Gutenberg-Universität Mainz
Universitätsmedizin der Johannes Gutenberg-Universität Mainz Medical/Nursing ServicesHealth Services Provides health care facilities and services | Health Services |
Ci3 Management UG | |
TRON - Translationale Onkologie an der Universitätsmedizin der
TRON - Translationale Onkologie an der Universitätsmedizin der Miscellaneous Commercial ServicesCommercial Services Operates as biopharmaceutical research organization | Commercial Services |
Medine GmbH
Medine GmbH Miscellaneous Commercial ServicesCommercial Services Provides management consultancy services | Commercial Services |
reBOOST Management GmbH
reBOOST Management GmbH Miscellaneous Commercial ServicesCommercial Services Provides management consultancy services | Commercial Services |
BioNTech Delivery Technologies GmbH
BioNTech Delivery Technologies GmbH Miscellaneous Commercial ServicesCommercial Services Engages in research and development of immunotherapies | Commercial Services |
Helmholtz Institute For Translational Oncology |
Kies jouw editie
Alle financiële informatie op nationaal niveau